Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Interventions
- Drug: TrastuzumabDrug: Doxorubicin HydrochlorideDrug: Epirubicin hydrochlorideDrug: FluorouracilDrug: PaclitaxelDrug: GemcitabineDrug: CisplatinDrug: Recombinant Human EndostatinDrug: Pirarubicin hydrochlorideDrug: PyrrolidineDrug: IxabepiloneDrug: Tamoxifen citrateDrug: Vinorelbine tartrateDrug: CarboplatinDrug: MethotrexateDrug: Eribulin mesylateDrug: Toremifene citrateDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: FulvestrantDrug: OlaparibDrug: BevacizumabDrug: Apatinib mesylateDrug: PattozumabDrug: CapecitabineDrug: Ear particlesDrug: Aidi InjectionDrug: Cyclophosphamide
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 5
- Registration Number
- NCT03393741
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 78
- Registration Number
- NCT03093155
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, United States
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 178
- Registration Number
- NCT02915744
- Locations
- 🇺🇸
Investigator Site - Plantation, Plantation, Florida, United States
🇺🇸Investigator Site - Boston, Boston, Massachusetts, United States
🇺🇸Investigator Site - Columbus, Columbus, Ohio, United States
Ixabepilone and SBRT For Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT01818999
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
- Conditions
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 38
- Registration Number
- NCT01446016
- Locations
- 🇺🇸
Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
🇺🇸Houston Methodist Hospital Cancer Center, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
A Study of LY2523355 in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01416389
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT01375829
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
- Conditions
- Interventions
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT01220609
- Locations
- 🇺🇸
John B Amos Cancer Center, Columbus, Georgia, United States
🇺🇸Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
🇺🇸Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.